"id","rationale","uuid:ID","instanceType","versionIdentifier"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","90c0e3f9-1ff9-496b-b95b-ab6bb0aa7f1d","StudyVersion","2"
